Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab in osteoarthritis of the knee or hip
NCT02447276Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2015
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of fasinumab in osteoarthritis (OA), sponsored by Regeneron Pharmaceuticals. Started May 2015; status: completed.
02
Drugs
fasinumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02447276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447276.